Terms ending in 2037
Every in-force patent on Immunocore Limited's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,739,442 | TCR Libraries In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 11,739,441 | TCR Libraries In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 10,835,577 | Peptides Derived from Kita-Kyushu Lung Cancer Antigen (KKLC1, CT83, CXORF61) and Complexes Comprising Such Peptides Bound to MHC Molecules In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 12,698,316 | Engineered Immune-Mobilizing T-Cell Receptors with Enhanced Affinity for HIV-1 Gag In force · Medium confidence | Immunocore Limited | In force | Medium confidence | |
| US 10,851,366 | Peptides Derived from Lengsin (LGSN), Complexes Comprising Such Peptides Bound to MHC Molecules In force · High confidence | Immunocore Limited | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.